CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-351

Agreed, I think an expansion in the indication for use to include closed angle is a potentially major catalyst for further revenue growth (I wonder if they're currently seeking this as part of the existing China FDA approval application?). It's still a very large market, but much less developed in terms of treatment options. We won't be competing against any other MIGS devices, when a doctor is presented with a closed angle case iTrack Advance will be the first and only device they think of. Hopefully the China approval comes quick, I have a feeling that's going to grow into a major market for this company over the next few years.